NF1 and MKI67 expression as prognostic biomarkers in ER+ metastatic breast cancer
Predicting outcomes in ER+ breast cancer using NF1 and MKI67 expression
Kaplan-Meier survival curves comparing rwPFS for NF1 and MKi67 groups in pre-treatment samples from ER+ BRCA patients anchored on 1L treatment start. Shaded areas represent the 95% confidence intervals. Median survival times (months) are specified. Log-Rank test P value is indicated. TPM thresholds for high/low expression are based on median expression within the overall cohort for MKI67 and the NF1-loss cohort for NF1.
Lens Library
